SciFluor’s DME drop treatment shows positive early study results

A topical ophthalmic solution for diabetic macular edema showed positive results in a phase 1/2 trial, according to a press release from SciFluor Life Sciences.SF0166, a selective small molecule inhibitor of integrin alpha V beta 3, was studied in 40 patients with DME who were randomly assigned to one of two dose strengths, 2.5% and 5%, twice a day for 28 days.

Full Story →